Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective
Introduction One in three patients with type 2 diabetes (T2D) suffers from any stage of chronic kidney disease (CKD), a chronic illness associated with a high global burden that impacts not only the healthcare system but also societal costs. Addition of finerenone to the standard of care (SoC) for p...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
BMJ Publishing Group
2025-06-01
|
| Цуврал: | BMJ Public Health |
| Онлайн хандалт: | https://bmjpublichealth.bmj.com/content/3/1/e001288.full |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|